Sangamo BioSciences, Inc.
| Nasdaq: SGMO
Sangamo BioSciences, Inc. is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. It is engaged in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. The company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic for the treatment of HIV/AIDS. Its other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Its product pipeline consists of SB-728 and SB-313. Sangamo BioSciences was founded by Lanphier O. Edward II on June 22, 1995 and is headquartered in Richmond, CA.